US Recall News

United States Recall News Alerts for Recalled Drugs, Food, Products, & Vehicles

MENUMENU
  • Home
  • About
    • Advertise
  • Full Recall News Archive
    • Top Story

      J&J Settles Talc Mesothelioma Settlement

      By Sandra Dalton, Staff Writer On January 6, 2020, Superior Court Judge Stephen Kaus announced that Johnson & Johnsons (J&J) had agreed to … [Read More...]

      Winston Products Recalls 5/8-Inch HydroTech Expandable Burst-Proof Hoses Due to Risk of Impact Hazard and Temporarily Impaired Hearing

      The recalled hoses can burst, posing an impact hazard and a risk of temporarily impaired hearing. … [Read More...]

    • More Safety Articles
    • Federal Preemption of State Product Liability Law
  • Drug Recalls
    • Abilify
    • Benicar
    • Fluoroquinolones
    • Invokana
    • Lipitor
    • Nuplazid
    • Opioids
    • OxyContin
    • Pradaxa
    • Proton Pump Inhibitors (PPIs)
    • Risperdal
    • SSRI
    • Symptoms & Side Effects
    • Taxotere
    • Testosterone
    • Uloric
    • Valsartan
    • Xarelto
    • Zofran
  • Medical Devices
    • 3M Earplug
    • 3T Heater-Cooler System
    • Bair Hugger
    • Bipolar Hip System
    • Essure
    • Hip Replacements
    • Implanon
    • IVC Filters
    • Hernia Mesh
    • Power Morcellators
    • Shoulder Implants
    • Transvaginal Mesh
  • Food Recalls
    • FDA Press Releases
    • USDA Press Releases
  • Auto Recalls
    • Air Bags
    • Ignitions
    • NHTSA Press Releases
    • Off-Road Utility Vehicles
    • Snowmobiles
    • Tires
  • Other Products
    • Asbestos
    • Baby Products
    • Pet Products
    • Roundup
    • Talcum Powder
    • Toy Recalls
You are here: Home / Food Recalls / FDA Press Releases / Sandoz, Inc. Issues Nationwide Recall of One Lot of Enoxaparin Sodium Injection, USP 40mg/0.4 mL Due to Temperature Excursion During Shipping

Sandoz, Inc. Issues Nationwide Recall of One Lot of Enoxaparin Sodium Injection, USP 40mg/0.4 mL Due to Temperature Excursion During Shipping

November 30, 2021 By The FDA Leave a Comment

Summary

Company Announcement Date:
December 01, 2021
FDA Publish Date:
December 02, 2021
Product Type:
Drugs

Reason for Announcement:

Recall Reason Description

Exposure to high temperatures may have impacted product effectiveness.

Company Name:
Sandoz, Inc.
Brand Name:

Brand Name(s)

Product Description:

Product Description

Enoxaparin Sodium Injection


Company Announcement

FOR IMMEDIATE RELEASE – December 1, 2021 – Princeton, NJ, Sandoz Inc. (“Sandoz”) is initiating a recall of one lot (SAB06761A, Exp 04/2023) of Enoxaparin Sodium Injection, USP 40 mg/0.4 mL Single-Dose Syringes to the consumer level. A portion of lot SAB06761A experienced a temperature excursion during shipment. Enoxaparin Sodium for Injection Lot SAB06761A was shipped to customers in the months of September and October 2021.

The exposure to higher temperatures may have significantly impacted the recalled product’s (lot SAB06761A) effectiveness and thus there may be reasonable probability of risk for patients with health conditions that the product is intended to treat. Such patients could be at risk for blood clots blocking blood vessels, an artery, or traveling to other tissues or organs causing pain, swelling, stroke, clots to the lung or death as a result of the underlying condition. To date, Sandoz has not received any reports of adverse events or injuries related to this recall.

The product is used for prevention of deep vein thrombosis (DVT) a condition that occurs when a blood clot forms in a deep vein, usually in the legs that can occur after surgeries or in patients with restricted mobility during illness; or prevention of complications associated with heart attacks. The product is packaged in cartons containing ten 0.4 mL syringes, NDC 0781-3246-64. Enoxaparin Sodium Injection was distributed Nationwide in the USA to wholesalers and retailers.

Product Name NDC Number Lot
Number
Expiration
Date
Date of
Manufacture
Enoxaparin Sodium
Injection, USP 40
mg/0.4 mL
00781-3246-64 SAB06761A 04/2023 05/26/2021

Please note: this recall is specific to only one batch (SAB06761A) of Enoxaparin Sodium Injection, USP 40 mg/0.4 mL and does not apply to any other strengths of Sandoz Enoxaparin Sodium Injection, USP or to other lots of the 40 mg/0.4 mL SKU.

Any product returned that is not associated with this recall will be destroyed and no credit issued.

Sandoz has already notified its wholesalers and retailers by mail and is arranging for return of all recalled product.

Consumers who have Enoxaparin Sodium Injection, USP 40 mg/0.4 mL (NDC 00781-3246-64 and Lot number SAB06761A) which is being recalled, should stop taking the recalled product, immediately consult with their physician to attain another prescription, and return the product where originally purchased. Consumers should contact their physician or healthcare provider if they have experienced any problems that may be related to taking or using this drug product.

Pharmacists should contact Sedgwick directly by phone at 844-265-7389 or by email at sandoz4623@sedgwick.com to request a recall packet. Representatives are available Monday – Friday, 8:00 am – 5:00 pm ET.

In case of any adverse reactions, please call Sandoz at (800) 525-8747 or email qa.drugsafety@sandoz.com. Customer service agents are available Monday – Friday from 8:30 am to 5:00 pm ET. Adverse events can also be reported to FDA online at www.fda.gov/medwatch/report.htm.

Adverse reactions or quality problems experienced with the use of this product may be reported to the FDA’s MedWatch Adverse Event Reporting program either online, by regular mail or by fax.

  • Complete and submit the report Online
  • Regular Mail or Fax: Download form or call 1- 800-332-1088 to request a reporting form, then complete and return to the address on the pre-addressed form, or submit by fax to 1-800-FDA-0178

This recall is being conducted with the knowledge of the U.S. Food and Drug Administration.

*Enoxaparin sodium injection is a product of Sandoz, Inc.

INDICATION AND IMPORTANT SAFETY INFORMATION

Please see full Prescribing Information for additional safety information.

Disclaimer

This press release contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements can generally be identified by words such as “potentially,” “can,” “will,” “may,” “could,” “initiating,” or similar terms, or by express or implied discussions regarding the potential outcome of the nationwide recall of Enoxaparin Sodium Injection 40MG Lot #SAB06761A, or regarding potential future revenues from such product. You should not place undue reliance on these statements. Such forward-looking statements are based on our current beliefs and expectations regarding future events and are subject to significant known and unknown risks and uncertainties. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those set forth in the forward-looking statements. There can be no guarantee as to the outcome of the nationwide recall of Enoxaparin Sodium Injection 40MG Lot #SAB06761A. In particular, our expectations regarding such product could be affected by, among other things, the uncertainties inherent in research and development, including clinical trial results and additional analysis of existing clinical data; regulatory actions or delays or government regulation generally; the particular prescribing preferences of physicians and patients; competition in general, including potential approval of additional generic or biosimilar versions of such product; global trends toward health care cost containment, including government, payor and general public pricing and reimbursement pressures and requirements for increased pricing transparency; litigation outcomes, including intellectual property disputes or other legal efforts to prevent or limit Sandoz from selling its products; general political, economic and business conditions, including the effects of and efforts to mitigate pandemic diseases such as COVID-19; safety, quality, data integrity or manufacturing issues; potential or actual data security and data privacy breaches, or disruptions of our information technology systems, and other risks and factors referred to in Novartis AG’s current Form 20-F on file with the US Securities and Exchange Commission. Novartis is providing the information in this press release as of this date and does not undertake any obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise.

About Sandoz

Sandoz, a Novartis division, is a global leader in generic pharmaceuticals and biosimilars. Our purpose is to pioneer access for patients by developing and commercializing novel, affordable approaches that address unmet medical need. Our ambition is to be the world’s leading and most valued generics company. Our broad portfolio of high-quality medicines, covering all major therapeutic areas, accounted for 2020 sales of USD 9.6 billion.

Sandoz on social media

LinkedIn: https://www.linkedin.com/company/sandoz/
Twitter: https://twitter.com/sandoz_global
Facebook: https://www.facebook.com/sandozglobal/
Instagram: https://www.instagram.com/sandozglobal

Novartis Media Relations

E-mail: media.relations@novartis.com

Julie Masow
Novartis US Communications
+1 862 579 8456 (mobile)
julie.masow@novartis.com

Leslie Pott
Sandoz US Communications
+1 201 354 0279 (mobile)
leslie.pott@sandoz.com

Novartis Investor Relations

Central Investor relations line: +41 61 324 7944
E-mail: investor.relations@novartis.com

North America
Sloan Simpson +1 862 778 5052


Company Contact Information

Share this:

  • Click to share on Facebook (Opens in new window) Facebook
  • Click to share on X (Opens in new window) X
  • Click to share on LinkedIn (Opens in new window) LinkedIn
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

Related

Filed Under: FDA Press Releases

About The FDA

The Food and Drug Administration (FDA) is an agency within the U.S. Department of Health and Human Services. It consists of the Office of the Commissioner and four directorates overseeing the core functions of the agency: Medical Products and Tobacco, Foods and Veterinary Medicine, Global Regulatory Operations and Policy, and Operations.

Leave a ReplyCancel reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.

Facebook
Thomas Roney LLC
Economic Consulting

J&J Settles Talc Mesothelioma Settlement

January 15, 2020 By Advice Media

Winston Products Recalls 5/8-Inch HydroTech Expandable Burst-Proof Hoses Due to Risk of Impact Hazard and Temporarily Impaired Hearing

July 23, 2025 By The CPSC

Curtis International Recalls Frigidaire-brand Minifridges Due to Fire and Burn Hazards; More Than $700,000 Reported in Property Damage

July 23, 2025 By The CPSC

Pura Scents Recalls Detachable Covers of Smart Home Fragrance Diffusers Due to Magnet Ingestion Hazard

July 23, 2025 By The CPSC

Hero Highlight

J&J Settles Talc Mesothelioma Settlement

January 15, 2020 By Advice Media

LED Gloves Recalled Due to Risk of Serious Injury or Death from Battery Ingestion; Violates the Mandatory Toy Standard and Child Resistant Coin Battery Packaging Standard; Sold on Amazon by Minongad

July 23, 2025 By The CPSC

Diamond G Forest Products Recalls Turpentine Bottles Due to Risk of Serious Injury or Death from Child Poisoning; Violates Mandatory Standard for Child Resistant Packaging

July 23, 2025 By The CPSC

Innovative Designs Recalls Minecraft Light-Up Slap Ruler Bracelets Due to Risk of Serious Injury or Death from Button Cell Battery Ingestion Hazard; Violates Mandatory Standard for Toys

July 23, 2025 By The CPSC

Creekwood Naturals Recalls 100% Natural Pure Gum Spirits of Turpentine Bottles Due to Risk of Serious Injury or Death from Child Poisoning; Violates Mandatory Standard for Child Resistant Packaging

July 23, 2025 By The CPSC

FENGQS Electric Bikes Recalled Due to Fire and Burn Hazards; Risk of Serious Injury or Death; Sold on Amazon

July 23, 2025 By The CPSC

J&J Settles Talc Mesothelioma Settlement

January 15, 2020 By Advice Media

Creekwood Naturals Recalls 100% Natural Pure Gum Spirits of Turpentine Bottles Due to Risk of Serious Injury or Death from Child Poisoning; Violates Mandatory Standard for Child Resistant Packaging

July 23, 2025 By The CPSC

FENGQS Electric Bikes Recalled Due to Fire and Burn Hazards; Risk of Serious Injury or Death; Sold on Amazon

July 23, 2025 By The CPSC

Aiho Dressers Recalled Due to Risk of Serious Injury or Death from Tip-Over and Entrapment; Violates Mandatory Standard; Sold on Walmart.com by Aiho

July 23, 2025 By The CPSC

Recall News in Your Inbox

Enter your email address to receive automated recall news updates.

Recent Comments

  • Roger McGowan on ABH NATURE’S PRODUCTS, INC, ABH PHARMA, INC., and STOCKNUTRA.COM, INC. Issues Nationwide Recall of All Lots of Dietary Supplement Products
  • Kathryn Moore on FDA Wants Cancer Warning on Breast Implants
  • BRAD on Huge ATV Recall by Polaris – Sportsman and Scrambler
  • Crystal Anderson on Allergan Voluntarily Recalls BIOCELL® Textured Breast Implants and Tissue Expanders
  • Outsourcing Training on The Modern Marketing of Pain
  • SANDRA Collett on Processed Food Preservative Linked to Autism?
  • Eric Karsh on Health Risks of Roundup Go Well Beyond Cancer

Recent Posts

  • Winston Products Recalls 5/8-Inch HydroTech Expandable Burst-Proof Hoses Due to Risk of Impact Hazard and Temporarily Impaired Hearing
  • Curtis International Recalls Frigidaire-brand Minifridges Due to Fire and Burn Hazards; More Than $700,000 Reported in Property Damage
  • Pura Scents Recalls Detachable Covers of Smart Home Fragrance Diffusers Due to Magnet Ingestion Hazard
  • iMirror Inc. Recalls Electric Bug Zapper Racket, Fly Swatter, and Mosquito Swatter Due to Shock Hazard
  • Transpro US Recalls Electric Scooters with Unauthorized Lithium-Ion Battery UL Certification Labels Due to Fire and Burn Hazards; Risk of Serious Injury and Death; $200,000 in Property Damage Reported
  • LED Gloves Recalled Due to Risk of Serious Injury or Death from Battery Ingestion; Violates the Mandatory Toy Standard and Child Resistant Coin Battery Packaging Standard; Sold on Amazon by Minongad
  • Diamond G Forest Products Recalls Turpentine Bottles Due to Risk of Serious Injury or Death from Child Poisoning; Violates Mandatory Standard for Child Resistant Packaging
  • Innovative Designs Recalls Minecraft Light-Up Slap Ruler Bracelets Due to Risk of Serious Injury or Death from Button Cell Battery Ingestion Hazard; Violates Mandatory Standard for Toys
  • Creekwood Naturals Recalls 100% Natural Pure Gum Spirits of Turpentine Bottles Due to Risk of Serious Injury or Death from Child Poisoning; Violates Mandatory Standard for Child Resistant Packaging
-- See More Recall News

Disclaimer: The information contained in these topics is not intended nor implied to be a substitute for professional medical or legal advice, it is provided for educational purposes only. Always seek the advice of your physician or other qualified healthcare provider about any questions you may have regarding a medical condition. Nothing contained in these topics is intended to be used for medical diagnosis or treatment.


ATTORNEY ADVERTISING. The information provided on this website is not legal advice. No attorney-client relationship is formed by the use of this site. It is not stated or implied that a lawyer is certified as a specialist in any particular field of law. No results are guaranteed, and prior results do not guarantee a similar outcome. This site is informational, only, not dispositive; it is up to you to decide whether a particular lawyer is right for you. Use of this site is subject to your agreement to these.


Copyright © 2025 Altrumedia · Terms of Service · Log in